Serum glial fibrillary acidic protein as a biomarker of brain injury in premature neonates

Serum glial fibrillary acidic protein as a biomarker of brain injury in premature neonates

Neonatal brain injury is a serious adverse outcome of prematurity. Early detection of high risk premature neonates to develop neonatal brain injury is not currently feasible. The predictive value of many biomarkers has been tested, but none is used currently in clinical practice. The purpose of this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomolecules & biomedicine 2022-02, Vol.22 (1), p.46-53
Hauptverfasser: Metallinou, Dimitra, Karampas, Grigorios, Nyktari, Georgia, Iacovidou, Nicoletta, Lykeridou, Katerina, Rizos, Demetrios
Format: Artikel
Sprache:eng
Schlagworte:
Biological markers
Biomarkers
Brain
Brain Injuries - diagnosis
Brain injury
Case-Control Studies
GFAP
Glial Fibrillary Acidic Protein - blood
Health aspects
Humans
Infant, Newborn
Infant, Premature
Infants (Premature)
Injuries
Intermediate filament proteins
intraventricular hemorrhage
Pediatric research
periventricular leukomalacia
premature neonates
Prospective Studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neonatal brain injury is a serious adverse outcome of prematurity. Early detection of high risk premature neonates to develop neonatal brain injury is not currently feasible. The predictive value of many biomarkers has been tested, but none is used currently in clinical practice. The purpose of this study was to determine the levels and predictive value of serum glial fibrillary acidic protein (GFAP) in a prospective longitudinal case-control study during the first three days of life in premature neonates (
ISSN:1512-8601
2831-0896
1840-4812
2831-090X
DOI:10.17305/bjbms.2021.6205